Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
1 other identifier
observational
1,546
1 country
2
Brief Summary
The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 7, 2020
CompletedFirst Submitted
Initial submission to the registry
June 8, 2020
CompletedFirst Posted
Study publicly available on registry
June 9, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2020
CompletedMarch 9, 2021
March 1, 2021
5 months
June 8, 2020
March 7, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies
3 Months
Study Arms (3)
Healthcare workers (HCWs)
Healthy blood donors and healthy subjects in blood bank
Convalescents
Interventions
A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).
Eligibility Criteria
Age-stratified sample from general population with 3 subgroups: 1. Healthcare workers (HCWs), comprising frontline doctors, nurses, health attendants, and receptionists. 2. Healthy blood donors and healthy subjects in blood bank or laboratory (routine examinations as pre-employment, likely to be representative of the general population 3. Convalescents
You may qualify if:
- Not previously diagnosed with COVID-19 except for convalescents
- Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea)
You may not qualify if:
- Patients with fever or respiratory symptoms (cough, dyspnea)
- Refusal to give informed consent, or contraindication to venipuncture.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Egyptian Center for Research and Regenerative Medicinelead
- Cairo Universitycollaborator
- National Research Centre, Egyptcollaborator
- Academy of Scientific Research and Technology, Egyptcollaborator
Study Sites (2)
ECRRM
Cairo, 32, Egypt
Faculty of Medicine, Cairo University
Cairo, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2020
First Posted
June 9, 2020
Study Start
June 7, 2020
Primary Completion
October 30, 2020
Study Completion
October 30, 2020
Last Updated
March 9, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will not share